Cipla Ltd · NSE:CIPLA
Cipla — Q1 FY2018 Earnings Presentation
13 slides from Cipla's earnings presentation, Aug 11, 2017
Slide 1: Investor Presentation Q1 FY18
Investor Presentation Q1 FY 18 11th Aug 2017 Investor Presentation: Q1 FY18 Confidential 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Highlights of the quarter
Highlights of the quarter US Launch Plan Sustained growth Manufacturing On target to momentum in and R&D sites in deliver 1 South Africa a state of control differentiated Key therapies & compliance product launch per retaining quarter starting leadership end Q2/Q3 position Developed Market Deepening
Slide 4: Most Respected in Pharma!
Most Respected in Pharma! Photograph AMIT PASRICHA Global Head, IPD Cipla GOA received Cipla Global SCM received FDD1 Achievement Award Award for Leadership Award for Healthy Workplace Maximum contribution from Express Pharma Conditions2 to Pharma Exports3 1 Formulations development and drug deliver
Slide 5: Financial Performance – Q1 FY18
Financial Performance – Q1 FY18 Revenues 3% (Majorly GST Impact) EBITDA 6% PAT 21% Q1 FY18 (Consolidated) Revenue1 Break-up Actuals vs Q1 FY Global Others, 2 (Rs Cr) 17 Europe, API, 4% 3% 4% Total Income from 3,525 -3% Operations India, a) Domestic Sales 1,303 -13% Emerging 36% Mkts, b) Int’l Sales
Slide 6: India (Rx + Gx) Sales
India (Rx + Gx) Sales Q1 Y-o-Y Q1 Q-o-Q Rs Cr Rs Cr 1600 1459 1400 6% 1271 -13% 1400 1271 1200 1194 1200 1000 1000 800 800 600 600 400 400 200 200 0 0 Q1 FY 17 Q1 FY 18 Q4 FY17 Q1 FY18 Key Business Highlights One of the leading pharma companies to transition successfully to GST on July 1 Busines
Slide 7: North America
North America Q1 Y-o-Y Q1 Q-o-Q $ Mn $ Mn 2% 100 4% 100 98 97 Q1 FY 17 Q1 FY 18 Q4 FY17 Q1 FY18 Key Business Highlights US launch plan progressing smoothly and on target to deliver 1 differentiated product launch starting end Q2/ Q3 4 new products launched in Q1 addressing a total market size of
Slide 8: ANDA Portfolio & Pipeline (As on 30th Jun'17)
ANDA1 Portfolio & Pipeline (As on 30th Jun’17) 238 Total 142 26 70 ANDAs ANDA Portfolio 160 140 120 37 100 80 54 7 60 6 22 40 4 20 45 4 1 13 37 0 8 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs Cipla Ltd PEPFAR 2 Invagen Partnered ANDAs 1 Does not include Vet product ANDAs 2 PEPFAR
Slide 9: South Africa
South Africa Q1 Y-o-Y Q1 Q-o-Q ZAR Mn ZAR Mn 1200 1200 10% 998 8% 998 1000 903 1000 923 800 800 600 600 400 400 200 200 0 0 Q1 FY17 Q1 FY18 Q4 FY17 Q1 FY18 Key Business Highlights Double digit y-o-y growth recorded in local currency despite conclusion of the sale of animal health business Strong
Slide 10: Emerging Markets
Emerging Markets1 Q1 Y-o-Y Q1 Q-o-Q $ Mn $ Mn 120 113 113 140 122 -7% 120 113 100 100 80 80 60 60 40 40 20 20 0 0 Q1 FY17 Q1 FY18 Q4 FY17 Q1 FY18 Key Business Highlights During the quarter, the business profitability improved driven by greater share of high margin SKUs in product mix Cipla Globa
Slide 11: Europe and API
Europe and API Europe $ Mn 30 Successful turnaround of the business 24 25 18 38% Q1 Growth of 38% year on year driven by 20 15 FPSM sales and strong performance 10 across B2B and DTM markets 5 0 Improvement in overall profitability Q1 FY17 Q1 FY18 driven by focus on high margin SKUs API Cons
Slide 12: Continued progress on key priorities
Continued progress on key priorities Key Priorities Q1 FY18 Update 4 launches executed in Q1FY18 with double digit market shares; On target to deliver 1 differentiated product launch per quarter starting end Q2/Q3 Accelerate scale-up 1 of US business Pipeline Update: - 3 ANDA filings in
Slide 13: Thank you
Thank you Contact details: Alpesh Dalal E-Mail: [email protected] Investor Presentation: Q1 FY18 Confidential 13